Denosumab increased significantly bone mass in all three dual X-ray absorptiometry standard sites, while alendronate did not at total hip.
No benefit was observed in men previously treated with alendronate who switched to denosumab treatment.
Autor: Planas Morin J, Celma Domenech A, Placer Santos J, Trilla Herrera E, Salvador Lacambra C,…
